ID   S22A5_HUMAN             Reviewed;         557 AA.
AC   O76082; A2Q0V1; B2R844; D3DQ87; Q6ZQZ8; Q96EH6;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1998, sequence version 1.
DT   10-MAY-2017, entry version 163.
DE   RecName: Full=Solute carrier family 22 member 5;
DE   AltName: Full=High-affinity sodium-dependent carnitine cotransporter;
DE   AltName: Full=Organic cation/carnitine transporter 2;
GN   Name=SLC22A5; Synonyms=OCTN2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9618255; DOI=10.1006/bbrc.1998.8669;
RA   Wu X., Prasad P.D., Leibach F.H., Ganapathy V.;
RT   "cDNA sequence, transport function, and genomic organization of human
RT   OCTN2, a new member of the organic cation transporter family.";
RL   Biochem. Biophys. Res. Commun. 246:589-595(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Kidney;
RX   PubMed=9685390; DOI=10.1074/jbc.273.32.20378;
RA   Tamai I., Ohashi R., Nezu J., Yabuuchi H., Oku A., Shimane M., Sai Y.,
RA   Tsuji A.;
RT   "Molecular and functional identification of sodium ion-dependent, high
RT   affinity human carnitine transporter OCTN2.";
RL   J. Biol. Chem. 273:20378-20382(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
RX   PubMed=9916797; DOI=10.1038/5030;
RA   Nezu J., Tamai I., Oku A., Ohashi R., Yabuuchi H., Hashimoto N.,
RA   Nikaido H., Sai Y., Koizumi A., Shoji Y., Takada G., Matsuishi T.,
RA   Yashino M., Kato H., Ohura T., Tsujimoto G., Hayakawa J., Shimane M.,
RA   Tsuji A.;
RT   "Primary systemic carnitine deficiency is caused by mutations in a
RT   gene encoding sodium ion-dependent carnitine transporter.";
RL   Nat. Genet. 21:91-94(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RX   PubMed=17509700; DOI=10.1016/j.bbamcr.2007.04.005;
RA   Maekawa S., Mori D., Nishiya T., Takikawa O., Horinouchi T.,
RA   Nishimoto A., Kajita E., Miwa S.;
RT   "OCTN2VT, a splice variant of OCTN2, does not transport carnitine
RT   because of the retention in the endoplasmic reticulum caused by
RT   insertion of 24 amino acids in the first extracellular loop of
RT   OCTN2.";
RL   Biochim. Biophys. Acta 1773:1000-1006(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T.,
RA   Gomez M., Gonzales E., Goodstein D., Grigoriev I., Groza M.,
RA   Hammon N., Hawkins T., Haydu L., Israni S., Jett J., Kadner K.,
RA   Kimball H., Kobayashi A., Lopez F., Lou Y., Martinez D., Medina C.,
RA   Morgan J., Nandkeshwar R., Noonan J.P., Pitluck S., Pollard M.,
RA   Predki P., Priest J., Ramirez L., Retterer J., Rodriguez A.,
RA   Rogers S., Salamov A., Salazar A., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., Dickson M.,
RA   Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., Rokhsar D.S.,
RA   Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=10454528;
RA   Wu X., Huang W., Prasad P.D., Seth P., Rajan D.P., Leibach F.H.,
RA   Chen J., Conway S.J., Ganapathy V.;
RT   "Functional characteristics and tissue distribution pattern of organic
RT   cation transporter 2 (OCTN2), an organic cation/carnitine
RT   transporter.";
RL   J. Pharmacol. Exp. Ther. 290:1482-1492(1999).
RN   [10]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-57 AND ASN-91.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19349973; DOI=10.1038/nbt.1532;
RA   Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M.,
RA   Schiess R., Aebersold R., Watts J.D.;
RT   "Mass-spectrometric identification and relative quantification of N-
RT   linked cell surface glycoproteins.";
RL   Nat. Biotechnol. 27:378-386(2009).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-486, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-550, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [13]
RP   VARIANT CDSP GLN-169.
RX   PubMed=10425211; DOI=10.1006/bbrc.1999.1060;
RA   Burwinkel B., Kreuder J., Schweitzer S., Vorgerd M., Gempel K.,
RA   Gerbitz K.-D., Kilimann M.W.;
RT   "Carnitine transporter OCTN2 mutations in systemic primary carnitine
RT   deficiency: a novel Arg169Gln mutation and a recurrent Arg282ter
RT   mutation associated with an unconventional splicing abnormality.";
RL   Biochem. Biophys. Res. Commun. 261:484-487(1999).
RN   [14]
RP   VARIANT CDSP CYS-211.
RX   PubMed=10480371; DOI=10.1007/s004399900105;
RA   Vaz F.M., Scholte H.R., Ruiter J., Hussaarts-Odijk L.M.,
RA   Rodrigues Pereira R., Schweitzer S., de Klerk J.B.C., Waterham H.R.,
RA   Wanders R.J.A.;
RT   "Identification of two novel mutations in OCTN2 of three patients with
RT   systemic carnitine deficiency.";
RL   Hum. Genet. 105:157-161(1999).
RN   [15]
RP   VARIANT CDSP LEU-478.
RX   PubMed=10072434; DOI=10.1093/hmg/8.4.655;
RA   Tang N.L., Ganapathy V., Wu X., Hui J., Seth P., Yuen P.M.,
RA   Wanders R.J., Fok T.F., Hjelm N.M.;
RT   "Mutations of OCTN2, an organic cation/carnitine transporter, lead to
RT   deficient cellular carnitine uptake in primary carnitine deficiency.";
RL   Hum. Mol. Genet. 8:655-660(1999).
RN   [16]
RP   VARIANTS CDSP LEU-179; CYS-283 AND CYS-467, AND CHARACTERIZATION OF
RP   VARIANTS CDSP LEU-179; CYS-283 AND CYS-467.
RX   PubMed=10545605; DOI=10.1093/hmg/8.12.2247;
RA   Koizumi A., Nozaki J., Ohura T., Kayo T., Wada Y., Nezu J., Ohashi R.,
RA   Tamai I., Shoji Y., Takada G., Kibira S., Matsuishi T., Tsuji A.;
RT   "Genetic epidemiology of the carnitine transporter OCTN2 gene in a
RT   Japanese population and phenotypic characterization in Japanese
RT   pedigrees with primary systemic carnitine deficiency.";
RL   Hum. Mol. Genet. 8:2247-2254(1999).
RN   [17]
RP   CHARACTERIZATION OF VARIANT CDSP LEU-478, AND MUTAGENESIS.
RX   PubMed=10559218; DOI=10.1074/jbc.274.47.33388;
RA   Seth P., Wu X., Huang W., Leibach F.H., Ganapathy V.;
RT   "Mutations in novel organic cation transporter (OCTN2), an organic
RT   cation/carnitine transporter, with differential effects on the organic
RT   cation transport function and the carnitine transport function.";
RL   J. Biol. Chem. 274:33388-33392(1999).
RN   [18]
RP   VARIANTS CDSP ARG-283 AND PHE-446.
RX   PubMed=10612840;
RX   DOI=10.1002/(SICI)1098-1004(200001)15:1<118::AID-HUMU28>3.0.CO;2-8;
RA   Mayatepek E., Nezu J., Tamai I., Oku A., Katsura M., Shimane M.,
RA   Tsuji A.;
RT   "Two novel missense mutations of the OCTN2 gene (W283R and V446F) in a
RT   patient with primary systemic carnitine deficiency.";
RL   Hum. Mutat. 15:118-118(2000).
RN   [19]
RP   SUBCELLULAR LOCATION, AND VARIANT CDSP LYS-452.
RX   PubMed=10679939;
RX   DOI=10.1002/(SICI)1098-1004(200003)15:3<238::AID-HUMU4>3.0.CO;2-3;
RA   Wang Y., Kelly M.A., Cowan T.M., Longo N.;
RT   "A missense mutation in the OCTN2 gene associated with residual
RT   carnitine transport activity.";
RL   Hum. Mutat. 15:238-245(2000).
RN   [20]
RP   VARIANTS CDSP TRP-169; VAL-242; ASP-301 AND ARG-351, AND
RP   CHARACTERIZATION OF VARIANTS CDSP TRP-169; VAL-242; ASP-301 AND
RP   ARG-351.
RX   PubMed=11058897;
RX   DOI=10.1002/1098-1004(200011)16:5<401::AID-HUMU4>3.0.CO;2-J;
RA   Wang Y., Taroni F., Garavaglia B., Longo N.;
RT   "Functional analysis of mutations in the OCTN2 transporter causing
RT   primary carnitine deficiency: lack of genotype-phenotype
RT   correlation.";
RL   Hum. Mutat. 16:401-407(2000).
RN   [21]
RP   VARIANTS CDSP PRO-19 AND GLN-399, AND CHARACTERIZATION OF VARIANTS
RP   CDSP PRO-19 AND GLN-399.
RX   PubMed=11715001; DOI=10.1097/00125817-200111000-00002;
RA   Wang Y., Korman S.H., Ye J., Gargus J.J., Gutman A., Taroni F.,
RA   Garavaglia B., Longo N.;
RT   "Phenotype and genotype variation in primary carnitine deficiency.";
RL   Genet. Med. 3:387-392(2001).
RN   [22]
RP   VARIANT CDSP LEU-83.
RX   PubMed=15617188; DOI=10.1023/B:BOLI.0000045837.23328.f4;
RA   Makhseed N., Vallance H.D., Potter M., Waters P.J., Wong L.T.K.,
RA   Lillquist Y., Pasquali M., Amat di San Filippo C., Longo N.;
RT   "Carnitine transporter defect due to a novel mutation in the SLC22A5
RT   gene presenting with peripheral neuropathy.";
RL   J. Inherit. Metab. Dis. 27:778-780(2004).
RN   [23]
RP   VARIANTS CDSP PRO-19; LEU-83; TRP-169; MET-232; VAL-242; ASP-301;
RP   ARG-351; GLN-399; CYS-447; ASP-449; LYS-452 AND ARG-468, AND
RP   CHARACTERIZATION OF VARIANTS MET-232 AND ARG-468.
RX   PubMed=15714519; DOI=10.1002/humu.20137;
RA   Dobrowolski S.F., McKinney J.T., Amat di San Filippo C., Giak Sim K.,
RA   Wilcken B., Longo N.;
RT   "Validation of dye-binding/high-resolution thermal denaturation for
RT   the identification of mutations in the SLC22A5 gene.";
RL   Hum. Mutat. 25:306-313(2005).
RN   [24]
RP   VARIANTS LEU-17; PHE-144; ASP-449; ILE-481; PHE-481; LEU-508; VAL-530
RP   AND SER-549.
RX   PubMed=16931768; DOI=10.1124/mol.106.028126;
RA   Urban T.J., Gallagher R.C., Brown C., Castro R.A., Lagpacan L.L.,
RA   Brett C.M., Taylor T.R., Carlson E.J., Ferrin T.E., Burchard E.G.,
RA   Packman S., Giacomini K.M.;
RT   "Functional genetic diversity in the high-affinity carnitine
RT   transporter OCTN2 (SLC22A5).";
RL   Mol. Pharmacol. 70:1602-1611(2006).
RN   [25]
RP   VARIANTS CDSP SER-32; SER-46; CYS-467 AND CYS-488, AND
RP   CHARACTERIZATION OF VARIANT CDSP SER-46.
RX   PubMed=17126586; DOI=10.1016/j.ymgme.2006.10.003;
RA   Schimmenti L.A., Crombez E.A., Schwahn B.C., Heese B.A., Wood T.C.,
RA   Schroer R.J., Bentler K., Cederbaum S., Sarafoglou K., McCann M.,
RA   Rinaldo P., Matern D., di San Filippo C.A., Pasquali M., Berry S.A.,
RA   Longo N.;
RT   "Expanded newborn screening identifies maternal primary carnitine
RT   deficiency.";
RL   Mol. Genet. Metab. 90:441-445(2007).
RN   [26]
RP   VARIANTS CDSP TRP-15; SER-46; LEU-83; SER-142; VAL-214; MET-232;
RP   TRP-399 AND ILE-442.
RX   PubMed=20027113; DOI=10.1097/GIM.0b013e3181c5e6f7;
RA   El-Hattab A.W., Li F.-Y., Shen J., Powell B.R., Bawle E.V.,
RA   Adams D.J., Wahl E., Kobori J.A., Graham B., Scaglia F., Wong L.-J.;
RT   "Maternal systemic primary carnitine deficiency uncovered by newborn
RT   screening: clinical, biochemical, and molecular aspects.";
RL   Genet. Med. 12:19-24(2010).
RN   [27]
RP   VARIANTS CDSP SER-12; TRP-15; LEU-17; SER-32; SER-46; LEU-83; TYR-122;
RP   SER-142; TRP-169; GLN-169; PRO-186; VAL-214; HIS-227; MET-232;
RP   TRP-257; ARG-264; GLN-282; LEU-355; LEU-398; TRP-399; MET-440;
RP   ILE-442; VAL-443; ASP-449; LYS-452; ARG-455; CYS-467; CYS-488 AND
RP   SER-507, AND VARIANTS PRO-66; PRO-75; ALA-96; GLY-123; LEU-143;
RP   VAL-177; LEU-230; THR-240; VAL-312; ASN-358 AND SER-549.
RX   PubMed=20574985; DOI=10.1002/humu.21311;
RA   Li F.-Y., El-Hattab A.W., Bawle E.V., Boles R.G., Schmitt E.S.,
RA   Scaglia F., Wong L.-J.;
RT   "Molecular spectrum of SLC22A5 (OCTN2) gene mutations detected in 143
RT   subjects evaluated for systemic carnitine deficiency.";
RL   Hum. Mutat. 31:E1632-E1651(2010).
RN   [28]
RP   VARIANTS CDSP LEU-17; ARG-234; GLN-282; LEU-362; CYS-467 AND CYS-471,
RP   AND VARIANT LEU-143.
RX   PubMed=20074989; DOI=10.1016/j.ymgme.2009.12.015;
RA   Lee N.-C., Tang N.-L., Chien Y.-H., Chen C.-A., Lin S.-J., Chiu P.-C.,
RA   Huang A.-C., Hwu W.-L.;
RT   "Diagnoses of newborns and mothers with carnitine uptake defects
RT   through newborn screening.";
RL   Mol. Genet. Metab. 100:46-50(2010).
RN   [29]
RP   VARIANTS CDSP TRP-15; PRO-19; PHE-22 DEL; ASN-26; SER-32; SER-46;
RP   LEU-83; SER-142; GLN-169; TRP-169; VAL-214; MET-232; PHE-280; GLN-282;
RP   ARG-283; ARG-351; MET-440; ILE-442; PHE-446; CYS-447; CYS-467; PRO-471
RP   AND HIS-488, AND CHARACTERIZATION OF VARIANTS CDSP TRP-15; PRO-19;
RP   PHE-22 DEL; ASN-26; SER-32; SER-46; LEU-83; GLN-169; TRP-169; VAL-214;
RP   MET-232; PHE-280; GLN-282; ARG-283; ARG-351; MET-440; ILE-442;
RP   PHE-446; CYS-447; CYS-467 AND PRO-471.
RX   PubMed=21922592; DOI=10.1002/humu.21607;
RA   Rose E.C., di San Filippo C.A., Ndukwe Erlingsson U.C., Ardon O.,
RA   Pasquali M., Longo N.;
RT   "Genotype-phenotype correlation in primary carnitine deficiency.";
RL   Hum. Mutat. 33:118-123(2012).
CC   -!- FUNCTION: Sodium-ion dependent, high affinity carnitine
CC       transporter. Involved in the active cellular uptake of carnitine.
CC       Transports one sodium ion with one molecule of carnitine. Also
CC       transports organic cations such as tetraethylammonium (TEA)
CC       without the involvement of sodium. Also relative uptake activity
CC       ratio of carnitine to TEA is 11.3. {ECO:0000269|PubMed:10454528}.
CC   -!- SUBUNIT: Interacts with PDZK1. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000269|PubMed:10679939};
CC       Multi-pass membrane protein {ECO:0000269|PubMed:10679939}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=O76082-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O76082-2; Sequence=VSP_011120, VSP_011121;
CC         Note=No experimental confirmation available.;
CC       Name=3; Synonyms=OCTN2VT;
CC         IsoId=O76082-3; Sequence=VSP_043904;
CC         Note=Retained in the ER, unable to perform carnitine uptake.;
CC   -!- TISSUE SPECIFICITY: Strongly expressed in kidney, skeletal muscle,
CC       heart and placenta. Highly expressed in intestinal cell types
CC       affected by Crohn disease, including epithelial cells. Expressed
CC       in CD68 macrophage and CD43 T-cells but not in CD20 B-cells.
CC       {ECO:0000269|PubMed:10454528}.
CC   -!- DISEASE: Systemic primary carnitine deficiency (CDSP)
CC       [MIM:212140]: Autosomal recessive disorder of fatty acid oxidation
CC       caused by defective carnitine transport. Present early in life
CC       with hypoketotic hypoglycemia and acute metabolic decompensation,
CC       or later in life with skeletal myopathy or cardiomyopathy.
CC       {ECO:0000269|PubMed:10072434, ECO:0000269|PubMed:10425211,
CC       ECO:0000269|PubMed:10480371, ECO:0000269|PubMed:10545605,
CC       ECO:0000269|PubMed:10559218, ECO:0000269|PubMed:10612840,
CC       ECO:0000269|PubMed:10679939, ECO:0000269|PubMed:11058897,
CC       ECO:0000269|PubMed:11715001, ECO:0000269|PubMed:15617188,
CC       ECO:0000269|PubMed:15714519, ECO:0000269|PubMed:17126586,
CC       ECO:0000269|PubMed:20027113, ECO:0000269|PubMed:20074989,
CC       ECO:0000269|PubMed:20574985, ECO:0000269|PubMed:21922592}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- MISCELLANEOUS: Inhibited by emetine, quinidine and verapamil. The
CC       IC(50) of emetine is 4.2 uM. Not inhibited by valproic acid.
CC   -!- SIMILARITY: Belongs to the major facilitator (TC 2.A.1)
CC       superfamily. Organic cation transporter (TC 2.A.1.19) family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=The SLC22A5 database;
CC       URL="http://www.arup.utah.edu/database/OCTN2/OCTN2_welcome.php";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF057164; AAC24828.1; -; mRNA.
DR   EMBL; AB015050; BAA29023.1; -; mRNA.
DR   EMBL; AB016625; BAA36712.1; -; Genomic_DNA.
DR   EMBL; AB291606; BAF45812.1; -; mRNA.
DR   EMBL; AK128610; BAC87527.1; -; mRNA.
DR   EMBL; AK313230; BAG36041.1; -; mRNA.
DR   EMBL; AC118464; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471062; EAW62337.1; -; Genomic_DNA.
DR   EMBL; CH471062; EAW62338.1; -; Genomic_DNA.
DR   EMBL; BC012325; AAH12325.1; -; mRNA.
DR   CCDS; CCDS4154.1; -. [O76082-1]
DR   CCDS; CCDS78058.1; -. [O76082-3]
DR   PIR; JW0089; JW0089.
DR   RefSeq; NP_001295051.1; NM_001308122.1. [O76082-3]
DR   RefSeq; NP_003051.1; NM_003060.3. [O76082-1]
DR   UniGene; Hs.443572; -.
DR   ProteinModelPortal; O76082; -.
DR   BioGrid; 112471; 5.
DR   IntAct; O76082; 5.
DR   STRING; 9606.ENSP00000245407; -.
DR   ChEMBL; CHEMBL2073693; -.
DR   DrugBank; DB08842; Acetylcarnitine.
DR   DrugBank; DB03128; Acetylcholine.
DR   DrugBank; DB04630; Aldosterone.
DR   DrugBank; DB00345; Aminohippuric acid.
DR   DrugBank; DB00182; Amphetamine.
DR   DrugBank; DB00415; Ampicillin.
DR   DrugBank; DB08795; Azidocillin.
DR   DrugBank; DB01053; Benzylpenicillin.
DR   DrugBank; DB01140; Cefadroxil.
DR   DrugBank; DB00456; Cefalotin.
DR   DrugBank; DB00535; Cefdinir.
DR   DrugBank; DB01413; Cefepime.
DR   DrugBank; DB00671; Cefixime.
DR   DrugBank; DB01333; Cefradine.
DR   DrugBank; DB00438; Ceftazidime.
DR   DrugBank; DB00567; Cephalexin.
DR   DrugBank; DB00689; Cephaloglycin.
DR   DrugBank; DB00122; Choline.
DR   DrugBank; DB00501; Cimetidine.
DR   DrugBank; DB00575; Clonidine.
DR   DrugBank; DB00148; Creatine.
DR   DrugBank; DB01000; Cyclacillin.
DR   DrugBank; DB00970; Dactinomycin.
DR   DrugBank; DB04133; Degraded Cephaloridine.
DR   DrugBank; DB01151; Desipramine.
DR   DrugBank; DB01075; Diphenhydramine.
DR   DrugBank; DB00988; Dopamine.
DR   DrugBank; DB00668; Epinephrine.
DR   DrugBank; DB00695; Furosemide.
DR   DrugBank; DB00365; Grepafloxacin.
DR   DrugBank; DB00536; Guanidine.
DR   DrugBank; DB00667; Histamine Phosphate.
DR   DrugBank; DB00332; Ipratropium bromide.
DR   DrugBank; DB00125; L-Arginine.
DR   DrugBank; DB00583; L-Carnitine.
DR   DrugBank; DB00281; Lidocaine.
DR   DrugBank; DB00978; Lomefloxacin.
DR   DrugBank; DB06691; Mepyramine.
DR   DrugBank; DB01577; Methamphetamine.
DR   DrugBank; DB00627; Niacin.
DR   DrugBank; DB00184; Nicotine.
DR   DrugBank; DB00368; Norepinephrine.
DR   DrugBank; DB01059; Norfloxacin.
DR   DrugBank; DB01165; Ofloxacin.
DR   DrugBank; DB01032; Probenecid.
DR   DrugBank; DB01035; Procainamide.
DR   DrugBank; DB00908; Quinidine.
DR   DrugBank; DB00468; Quinine.
DR   DrugBank; DB01208; Sparfloxacin.
DR   DrugBank; DB08837; Tetraethylammonium.
DR   DrugBank; DB00152; Thiamine.
DR   DrugBank; DB01409; Tiotropium.
DR   DrugBank; DB00313; Valproic Acid.
DR   DrugBank; DB00661; Verapamil.
DR   TCDB; 2.A.1.19.3; the major facilitator superfamily (mfs).
DR   iPTMnet; O76082; -.
DR   PhosphoSitePlus; O76082; -.
DR   BioMuta; SLC22A5; -.
DR   MaxQB; O76082; -.
DR   PaxDb; O76082; -.
DR   PeptideAtlas; O76082; -.
DR   PRIDE; O76082; -.
DR   DNASU; 6584; -.
DR   Ensembl; ENST00000245407; ENSP00000245407; ENSG00000197375. [O76082-1]
DR   Ensembl; ENST00000435065; ENSP00000402760; ENSG00000197375. [O76082-3]
DR   GeneID; 6584; -.
DR   KEGG; hsa:6584; -.
DR   UCSC; uc003kww.5; human. [O76082-1]
DR   CTD; 6584; -.
DR   DisGeNET; 6584; -.
DR   GeneCards; SLC22A5; -.
DR   GeneReviews; SLC22A5; -.
DR   HGNC; HGNC:10969; SLC22A5.
DR   HPA; HPA063062; -.
DR   MalaCards; SLC22A5; -.
DR   MIM; 212140; phenotype.
DR   MIM; 603377; gene.
DR   neXtProt; NX_O76082; -.
DR   OpenTargets; ENSG00000197375; -.
DR   Orphanet; 158; Systemic primary carnitine deficiency.
DR   PharmGKB; PA333; -.
DR   eggNOG; ENOG410IRIE; Eukaryota.
DR   eggNOG; ENOG410XSRI; LUCA.
DR   GeneTree; ENSGT00760000118852; -.
DR   HOGENOM; HOG000234570; -.
DR   HOVERGEN; HBG061545; -.
DR   InParanoid; O76082; -.
DR   KO; K08202; -.
DR   OMA; TRNIRMI; -.
DR   OrthoDB; EOG091G05AC; -.
DR   PhylomeDB; O76082; -.
DR   TreeFam; TF315847; -.
DR   Reactome; R-HSA-549127; Organic cation transport.
DR   GeneWiki; SLC22A5; -.
DR   GenomeRNAi; 6584; -.
DR   PRO; PR:O76082; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; ENSG00000197375; -.
DR   CleanEx; HS_SLC22A5; -.
DR   ExpressionAtlas; O76082; baseline and differential.
DR   Genevisible; O76082; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0031526; C:brush border membrane; IDA:BHF-UCL.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0015226; F:carnitine transmembrane transporter activity; IDA:BHF-UCL.
DR   GO; GO:0015491; F:cation:cation antiporter activity; IBA:GO_Central.
DR   GO; GO:0015238; F:drug transmembrane transporter activity; IC:BHF-UCL.
DR   GO; GO:0008514; F:organic anion transmembrane transporter activity; IBA:GO_Central.
DR   GO; GO:0030165; F:PDZ domain binding; IPI:BHF-UCL.
DR   GO; GO:0015651; F:quaternary ammonium group transmembrane transporter activity; IDA:BHF-UCL.
DR   GO; GO:0015293; F:symporter activity; IEA:UniProtKB-KW.
DR   GO; GO:0009437; P:carnitine metabolic process; IBA:GO_Central.
DR   GO; GO:0015879; P:carnitine transport; IDA:BHF-UCL.
DR   GO; GO:0015893; P:drug transport; IC:BHF-UCL.
DR   GO; GO:0060731; P:positive regulation of intestinal epithelial structure maintenance; IMP:BHF-UCL.
DR   GO; GO:0015697; P:quaternary ammonium group transport; IDA:BHF-UCL.
DR   GO; GO:0052106; P:quorum sensing involved in interaction with host; IMP:BHF-UCL.
DR   GO; GO:0006814; P:sodium ion transport; IEA:UniProtKB-KW.
DR   GO; GO:0070715; P:sodium-dependent organic cation transport; IDA:BHF-UCL.
DR   CDD; cd06174; MFS; 1.
DR   InterPro; IPR020846; MFS_dom.
DR   InterPro; IPR005828; MFS_sugar_transport-like.
DR   InterPro; IPR004749; Orgcat_transp/SVOP.
DR   InterPro; IPR005829; Sugar_transporter_CS.
DR   Pfam; PF00083; Sugar_tr; 1.
DR   SUPFAM; SSF103473; SSF103473; 1.
DR   TIGRFAMs; TIGR00898; 2A0119; 1.
DR   PROSITE; PS50850; MFS; 1.
DR   PROSITE; PS00216; SUGAR_TRANSPORT_1; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Complete proteome;
KW   Disease mutation; Glycoprotein; Ion transport; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Reference proteome;
KW   Sodium; Sodium transport; Symport; Transmembrane; Transmembrane helix;
KW   Transport.
FT   CHAIN         1    557       Solute carrier family 22 member 5.
FT                                /FTId=PRO_0000220500.
FT   TOPO_DOM      1     20       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     21     41       Helical; Name=1. {ECO:0000255}.
FT   TOPO_DOM     42    142       Extracellular. {ECO:0000255}.
FT   TRANSMEM    143    163       Helical; Name=2. {ECO:0000255}.
FT   TOPO_DOM    164    172       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    173    193       Helical; Name=3. {ECO:0000255}.
FT   TOPO_DOM    194    197       Extracellular. {ECO:0000255}.
FT   TRANSMEM    198    218       Helical; Name=4. {ECO:0000255}.
FT   TOPO_DOM    219    232       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    233    253       Helical; Name=5. {ECO:0000255}.
FT   TOPO_DOM    254    257       Extracellular. {ECO:0000255}.
FT   TRANSMEM    258    278       Helical; Name=6. {ECO:0000255}.
FT   TOPO_DOM    279    341       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    342    362       Helical; Name=7. {ECO:0000255}.
FT   TOPO_DOM    363    373       Extracellular. {ECO:0000255}.
FT   TRANSMEM    374    394       Helical; Name=8. {ECO:0000255}.
FT   TOPO_DOM    395    406       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    407    427       Helical; Name=9. {ECO:0000255}.
FT   TOPO_DOM    428    430       Extracellular. {ECO:0000255}.
FT   TRANSMEM    431    451       Helical; Name=10. {ECO:0000255}.
FT   TOPO_DOM    452    462       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    463    483       Helical; Name=11. {ECO:0000255}.
FT   TOPO_DOM    484    488       Extracellular. {ECO:0000255}.
FT   TRANSMEM    489    509       Helical; Name=12. {ECO:0000255}.
FT   NP_BIND     218    225       ATP. {ECO:0000255}.
FT   MOD_RES     486    486       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     550    550       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   CARBOHYD     57     57       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19349973}.
FT   CARBOHYD     64     64       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD     91     91       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19349973}.
FT   VAR_SEQ       1    336       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_011120.
FT   VAR_SEQ     131    131       E -> EQDSGAYNAMKNRMGKKPALCLPAQ (in
FT                                isoform 3).
FT                                {ECO:0000303|PubMed:17509700}.
FT                                /FTId=VSP_043904.
FT   VAR_SEQ     337    351       TWNIRMVTIMSIMLW -> MWILLFQLSSALCFR (in
FT                                isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_011121.
FT   VARIANT      12     12       G -> S (in CDSP; dbSNP:rs139203363).
FT                                {ECO:0000269|PubMed:20574985}.
FT                                /FTId=VAR_064109.
FT   VARIANT      15     15       G -> W (in CDSP; dbSNP:rs267607052).
FT                                {ECO:0000269|PubMed:20027113,
FT                                ECO:0000269|PubMed:20574985,
FT                                ECO:0000269|PubMed:21922592}.
FT                                /FTId=VAR_064110.
FT   VARIANT      17     17       F -> L (in CDSP; dbSNP:rs11568520).
FT                                {ECO:0000269|PubMed:16931768,
FT                                ECO:0000269|PubMed:20074989,
FT                                ECO:0000269|PubMed:20574985}.
FT                                /FTId=VAR_020347.
FT   VARIANT      19     19       R -> P (in CDSP; carnitine transport is
FT                                reduced to less than 5% of normal;
FT                                dbSNP:rs72552723).
FT                                {ECO:0000269|PubMed:11715001,
FT                                ECO:0000269|PubMed:15714519,
FT                                ECO:0000269|PubMed:21922592}.
FT                                /FTId=VAR_064111.
FT   VARIANT      22     22       Missing (in CDSP; reduces carnitine
FT                                transport).
FT                                {ECO:0000269|PubMed:21922592}.
FT                                /FTId=VAR_066842.
FT   VARIANT      26     26       S -> N (in CDSP; reduces carnitine
FT                                transport; dbSNP:rs772578415).
FT                                {ECO:0000269|PubMed:21922592}.
FT                                /FTId=VAR_066843.
FT   VARIANT      32     32       N -> S (in CDSP; reduces carnitine
FT                                transport; dbSNP:rs72552725).
FT                                {ECO:0000269|PubMed:17126586,
FT                                ECO:0000269|PubMed:20574985,
FT                                ECO:0000269|PubMed:21922592}.
FT                                /FTId=VAR_064112.
FT   VARIANT      46     46       P -> S (in CDSP; carnitine transport is
FT                                reduced to less than 5% of normal;
FT                                dbSNP:rs202088921).
FT                                {ECO:0000269|PubMed:17126586,
FT                                ECO:0000269|PubMed:20027113,
FT                                ECO:0000269|PubMed:20574985,
FT                                ECO:0000269|PubMed:21922592}.
FT                                /FTId=VAR_064113.
FT   VARIANT      66     66       T -> P (associated with CDSP;
FT                                unclassified missense variant).
FT                                {ECO:0000269|PubMed:20574985}.
FT                                /FTId=VAR_064114.
FT   VARIANT      75     75       R -> P (associated with CDSP;
FT                                unclassified missense variant;
FT                                dbSNP:rs757711838).
FT                                {ECO:0000269|PubMed:20574985}.
FT                                /FTId=VAR_064115.
FT   VARIANT      83     83       R -> L (in CDSP; reduces carnitine
FT                                transport; dbSNP:rs72552726).
FT                                {ECO:0000269|PubMed:15617188,
FT                                ECO:0000269|PubMed:15714519,
FT                                ECO:0000269|PubMed:20027113,
FT                                ECO:0000269|PubMed:20574985,
FT                                ECO:0000269|PubMed:21922592}.
FT                                /FTId=VAR_064116.
FT   VARIANT      96     96       G -> A (associated with CDSP;
FT                                unclassified missense variant;
FT                                dbSNP:rs377767450).
FT                                {ECO:0000269|PubMed:20574985}.
FT                                /FTId=VAR_064117.
FT   VARIANT     122    122       D -> Y (in CDSP; dbSNP:rs201082652).
FT                                {ECO:0000269|PubMed:20574985}.
FT                                /FTId=VAR_064118.
FT   VARIANT     123    123       V -> G (associated with CDSP;
FT                                unclassified missense variant;
FT                                dbSNP:rs748605096).
FT                                {ECO:0000269|PubMed:20574985}.
FT                                /FTId=VAR_064119.
FT   VARIANT     142    142       A -> S (in CDSP; dbSNP:rs151231558).
FT                                {ECO:0000269|PubMed:20027113,
FT                                ECO:0000269|PubMed:20574985,
FT                                ECO:0000269|PubMed:21922592}.
FT                                /FTId=VAR_064120.
FT   VARIANT     143    143       P -> L (associated with CDSP;
FT                                unclassified missense variant).
FT                                {ECO:0000269|PubMed:20074989,
FT                                ECO:0000269|PubMed:20574985}.
FT                                /FTId=VAR_064121.
FT   VARIANT     144    144       L -> F (in dbSNP:rs10040427).
FT                                {ECO:0000269|PubMed:16931768}.
FT                                /FTId=VAR_020348.
FT   VARIANT     169    169       R -> Q (in CDSP; reduces carnitine
FT                                transport; dbSNP:rs121908889).
FT                                {ECO:0000269|PubMed:10425211,
FT                                ECO:0000269|PubMed:20574985,
FT                                ECO:0000269|PubMed:21922592}.
FT                                /FTId=VAR_009252.
FT   VARIANT     169    169       R -> W (in CDSP; abolishes carnitine
FT                                transport; dbSNP:rs121908890).
FT                                {ECO:0000269|PubMed:11058897,
FT                                ECO:0000269|PubMed:15714519,
FT                                ECO:0000269|PubMed:20574985,
FT                                ECO:0000269|PubMed:21922592}.
FT                                /FTId=VAR_064122.
FT   VARIANT     177    177       M -> V (associated with CDSP;
FT                                unclassified missense variant;
FT                                dbSNP:rs145068530).
FT                                {ECO:0000269|PubMed:20574985}.
FT                                /FTId=VAR_064123.
FT   VARIANT     179    179       M -> L (in CDSP; dbSNP:rs386134196).
FT                                {ECO:0000269|PubMed:10545605}.
FT                                /FTId=VAR_022564.
FT   VARIANT     186    186       L -> P (in CDSP; dbSNP:rs386134197).
FT                                {ECO:0000269|PubMed:20574985}.
FT                                /FTId=VAR_064124.
FT   VARIANT     211    211       Y -> C (in CDSP; dbSNP:rs121908888).
FT                                {ECO:0000269|PubMed:10480371}.
FT                                /FTId=VAR_009253.
FT   VARIANT     214    214       A -> V (in CDSP; reduces carnitine
FT                                transport; dbSNP:rs386134199).
FT                                {ECO:0000269|PubMed:20027113,
FT                                ECO:0000269|PubMed:20574985,
FT                                ECO:0000269|PubMed:21922592}.
FT                                /FTId=VAR_064125.
FT   VARIANT     227    227       R -> H (in CDSP; dbSNP:rs185551386).
FT                                {ECO:0000269|PubMed:20574985}.
FT                                /FTId=VAR_064126.
FT   VARIANT     230    230       F -> L (associated with CDSP;
FT                                unclassified missense variant;
FT                                dbSNP:rs756650860).
FT                                {ECO:0000269|PubMed:20574985}.
FT                                /FTId=VAR_064127.
FT   VARIANT     232    232       T -> M (in CDSP; markedly reduced
FT                                carnitine transport compared to the wild-
FT                                type protein; dbSNP:rs114269482).
FT                                {ECO:0000269|PubMed:15714519,
FT                                ECO:0000269|PubMed:20027113,
FT                                ECO:0000269|PubMed:20574985,
FT                                ECO:0000269|PubMed:21922592}.
FT                                /FTId=VAR_064128.
FT   VARIANT     234    234       G -> R (in CDSP).
FT                                {ECO:0000269|PubMed:20074989}.
FT                                /FTId=VAR_064129.
FT   VARIANT     240    240       A -> T (associated with CDSP;
FT                                unclassified missense variant).
FT                                {ECO:0000269|PubMed:20574985}.
FT                                /FTId=VAR_064130.
FT   VARIANT     242    242       G -> V (in CDSP; abolishes carnitine
FT                                transport; dbSNP:rs72552728).
FT                                {ECO:0000269|PubMed:11058897,
FT                                ECO:0000269|PubMed:15714519}.
FT                                /FTId=VAR_064131.
FT   VARIANT     257    257       R -> W (in CDSP; dbSNP:rs386134203).
FT                                {ECO:0000269|PubMed:20574985}.
FT                                /FTId=VAR_064132.
FT   VARIANT     264    264       T -> R (in CDSP; dbSNP:rs201262157).
FT                                {ECO:0000269|PubMed:20574985}.
FT                                /FTId=VAR_064133.
FT   VARIANT     280    280       S -> F (in CDSP; reduces carnitine
FT                                transport; dbSNP:rs386134208).
FT                                {ECO:0000269|PubMed:21922592}.
FT                                /FTId=VAR_066844.
FT   VARIANT     282    282       R -> Q (in CDSP; reduces carnitine
FT                                transport; dbSNP:rs386134210).
FT                                {ECO:0000269|PubMed:20074989,
FT                                ECO:0000269|PubMed:20574985,
FT                                ECO:0000269|PubMed:21922592}.
FT                                /FTId=VAR_064134.
FT   VARIANT     283    283       W -> C (in CDSP; reduces L-carnitine
FT                                uptake; dbSNP:rs386134211).
FT                                {ECO:0000269|PubMed:10545605}.
FT                                /FTId=VAR_022565.
FT   VARIANT     283    283       W -> R (in CDSP; reduces carnitine
FT                                transport; dbSNP:rs72552729).
FT                                {ECO:0000269|PubMed:10612840,
FT                                ECO:0000269|PubMed:21922592}.
FT                                /FTId=VAR_009254.
FT   VARIANT     301    301       A -> D (in CDSP; has 2-3% residual
FT                                carnitine transport of the value measured
FT                                in cells expressing the wild-type
FT                                protein; dbSNP:rs72552730).
FT                                {ECO:0000269|PubMed:11058897,
FT                                ECO:0000269|PubMed:15714519}.
FT                                /FTId=VAR_064135.
FT   VARIANT     312    312       I -> V (associated with CDSP;
FT                                unclassified missense variant;
FT                                dbSNP:rs77300588).
FT                                {ECO:0000269|PubMed:20574985}.
FT                                /FTId=VAR_064136.
FT   VARIANT     351    351       W -> R (in CDSP; abolishes carnitine
FT                                transport; dbSNP:rs68018207).
FT                                {ECO:0000269|PubMed:11058897,
FT                                ECO:0000269|PubMed:15714519,
FT                                ECO:0000269|PubMed:21922592}.
FT                                /FTId=VAR_064137.
FT   VARIANT     355    355       S -> L (in CDSP).
FT                                {ECO:0000269|PubMed:20574985}.
FT                                /FTId=VAR_064138.
FT   VARIANT     358    358       Y -> N (associated with CDSP;
FT                                unclassified missense variant;
FT                                dbSNP:rs61731073).
FT                                {ECO:0000269|PubMed:20574985}.
FT                                /FTId=VAR_064139.
FT   VARIANT     362    362       S -> L (in CDSP).
FT                                {ECO:0000269|PubMed:20074989}.
FT                                /FTId=VAR_064140.
FT   VARIANT     398    398       P -> L (in CDSP; dbSNP:rs144547521).
FT                                {ECO:0000269|PubMed:20574985}.
FT                                /FTId=VAR_064141.
FT   VARIANT     399    399       R -> Q (in CDSP; carnitine transport is
FT                                reduced to less than 5% of normal;
FT                                dbSNP:rs121908891).
FT                                {ECO:0000269|PubMed:11715001,
FT                                ECO:0000269|PubMed:15714519}.
FT                                /FTId=VAR_064142.
FT   VARIANT     399    399       R -> W (in CDSP; dbSNP:rs267607054).
FT                                {ECO:0000269|PubMed:20027113,
FT                                ECO:0000269|PubMed:20574985}.
FT                                /FTId=VAR_064143.
FT   VARIANT     440    440       T -> M (in CDSP; reduces carnitine
FT                                transport; dbSNP:rs72552732).
FT                                {ECO:0000269|PubMed:20574985,
FT                                ECO:0000269|PubMed:21922592}.
FT                                /FTId=VAR_064144.
FT   VARIANT     442    442       A -> I (in CDSP; requires 2 nucleotide
FT                                substitutions; reduces carnitine
FT                                transport; dbSNP:rs267607053).
FT                                {ECO:0000269|PubMed:20027113,
FT                                ECO:0000269|PubMed:20574985,
FT                                ECO:0000269|PubMed:21922592}.
FT                                /FTId=VAR_064145.
FT   VARIANT     443    443       F -> V (in CDSP).
FT                                {ECO:0000269|PubMed:20574985}.
FT                                /FTId=VAR_064146.
FT   VARIANT     446    446       V -> F (in CDSP; reduces carnitine
FT                                transport; dbSNP:rs72552733).
FT                                {ECO:0000269|PubMed:10612840,
FT                                ECO:0000269|PubMed:21922592}.
FT                                /FTId=VAR_009255.
FT   VARIANT     447    447       Y -> C (in CDSP; reduces carnitine
FT                                transport; dbSNP:rs386134218).
FT                                {ECO:0000269|PubMed:15714519,
FT                                ECO:0000269|PubMed:21922592}.
FT                                /FTId=VAR_064147.
FT   VARIANT     449    449       Y -> D (in CDSP; dbSNP:rs11568514).
FT                                {ECO:0000269|PubMed:15714519,
FT                                ECO:0000269|PubMed:16931768,
FT                                ECO:0000269|PubMed:20574985}.
FT                                /FTId=VAR_029315.
FT   VARIANT     452    452       E -> K (in CDSP; dbSNP:rs72552734).
FT                                {ECO:0000269|PubMed:10679939,
FT                                ECO:0000269|PubMed:15714519,
FT                                ECO:0000269|PubMed:20574985}.
FT                                /FTId=VAR_009256.
FT   VARIANT     455    455       P -> R (in CDSP).
FT                                {ECO:0000269|PubMed:20574985}.
FT                                /FTId=VAR_064148.
FT   VARIANT     467    467       S -> C (in CDSP; reduces L-carnitine
FT                                uptake; dbSNP:rs60376624).
FT                                {ECO:0000269|PubMed:10545605,
FT                                ECO:0000269|PubMed:17126586,
FT                                ECO:0000269|PubMed:20074989,
FT                                ECO:0000269|PubMed:20574985,
FT                                ECO:0000269|PubMed:21922592}.
FT                                /FTId=VAR_022566.
FT   VARIANT     468    468       T -> R (in CDSP; markedly reduced
FT                                carnitine transport compared to the wild-
FT                                type protein; dbSNP:rs386134221).
FT                                {ECO:0000269|PubMed:15714519}.
FT                                /FTId=VAR_064149.
FT   VARIANT     471    471       R -> C (in CDSP; dbSNP:rs749282641).
FT                                {ECO:0000269|PubMed:20074989}.
FT                                /FTId=VAR_064150.
FT   VARIANT     471    471       R -> P (in CDSP; reduces carnitine
FT                                transport).
FT                                {ECO:0000269|PubMed:21922592}.
FT                                /FTId=VAR_066845.
FT   VARIANT     478    478       P -> L (in CDSP; loss of carnitine
FT                                transport but stimulated organic cation
FT                                transport; dbSNP:rs72552735).
FT                                {ECO:0000269|PubMed:10072434,
FT                                ECO:0000269|PubMed:10559218}.
FT                                /FTId=VAR_009257.
FT   VARIANT     481    481       V -> F (in dbSNP:rs11568513).
FT                                {ECO:0000269|PubMed:16931768}.
FT                                /FTId=VAR_020349.
FT   VARIANT     481    481       V -> I (in dbSNP:rs11568513).
FT                                {ECO:0000269|PubMed:16931768}.
FT                                /FTId=VAR_036816.
FT   VARIANT     488    488       R -> C (in CDSP; dbSNP:rs377216516).
FT                                {ECO:0000269|PubMed:17126586,
FT                                ECO:0000269|PubMed:20574985}.
FT                                /FTId=VAR_064151.
FT   VARIANT     488    488       R -> H (in CDSP; reduces carnitine
FT                                transport; dbSNP:rs28383481).
FT                                {ECO:0000269|PubMed:21922592}.
FT                                /FTId=VAR_066846.
FT   VARIANT     507    507       L -> S (in CDSP).
FT                                {ECO:0000269|PubMed:20574985}.
FT                                /FTId=VAR_064152.
FT   VARIANT     508    508       F -> L (in dbSNP:rs11568521).
FT                                {ECO:0000269|PubMed:16931768}.
FT                                /FTId=VAR_029316.
FT   VARIANT     530    530       M -> V (in dbSNP:rs11568524).
FT                                {ECO:0000269|PubMed:16931768}.
FT                                /FTId=VAR_029317.
FT   VARIANT     549    549       P -> S (associated with CDSP;
FT                                unclassified missense variant;
FT                                dbSNP:rs11568525).
FT                                {ECO:0000269|PubMed:16931768,
FT                                ECO:0000269|PubMed:20574985}.
FT                                /FTId=VAR_020350.
FT   MUTAGEN     352    352       M->R: Loss of both carnitine and organic
FT                                cation transport functionalities.
FT                                {ECO:0000269|PubMed:10559218}.
FT   CONFLICT    114    114       L -> P (in Ref. 8; AAH12325).
FT                                {ECO:0000305}.
SQ   SEQUENCE   557 AA;  62752 MW;  928B1F6EFF63C48D CRC64;
     MRDYDEVTAF LGEWGPFQRL IFFLLSASII PNGFTGLSSV FLIATPEHRC RVPDAANLSS
     AWRNHTVPLR LRDGREVPHS CRRYRLATIA NFSALGLEPG RDVDLGQLEQ ESCLDGWEFS
     QDVYLSTIVT EWNLVCEDDW KAPLTISLFF VGVLLGSFIS GQLSDRFGRK NVLFVTMGMQ
     TGFSFLQIFS KNFEMFVVLF VLVGMGQISN YVAAFVLGTE ILGKSVRIIF STLGVCIFYA
     FGYMVLPLFA YFIRDWRMLL VALTMPGVLC VALWWFIPES PRWLISQGRF EEAEVIIRKA
     AKANGIVVPS TIFDPSELQD LSSKKQQSHN ILDLLRTWNI RMVTIMSIML WMTISVGYFG
     LSLDTPNLHG DIFVNCFLSA MVEVPAYVLA WLLLQYLPRR YSMATALFLG GSVLLFMQLV
     PPDLYYLATV LVMVGKFGVT AAFSMVYVYT AELYPTVVRN MGVGVSSTAS RLGSILSPYF
     VYLGAYDRFL PYILMGSLTI LTAILTLFLP ESFGTPLPDT IDQMLRVKGM KHRKTPSHTR
     MLKDGQERPT ILKSTAF
//
